# Biolab acquires Actavis Brasil from Teva

Biolab has acquired Actavis Brasil from Teva, gaining a factory in Rio de Janeiro and a portfolio of 30 products. The deal was concluded in late June 2018; the value is undisclosed but estimated at R$ 40-60 million.

- Type: Acquisition
- Announced: 2018-07-04
- Where: Rio de Janeiro, Brazil
- Value: $13.0M (50.0M BRL)
- Status: completed
- Products: generic drugs, central nervous system drugs

## Companies

- [Biolab](https://endata.com/companies/32939.md) (acquirer)
- [Actavis Brasil](https://endata.com/companies/32940.md) (target)
- [Teva](https://endata.com/companies/32941.md) (partner)

## Sources

- [biolabeco.com.br](https://www.biolabeco.com.br/en/press/biolab-enters-generics-and-evaluates-purchase-in-canada/), 2018-07-04: "We're going to play in generics, but without giving up Biolab's DNA, which is innovation."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.